Madrigal Pharmaceuticals Secures $4.4B Deal for Six Preclinical siRNA Programs Targeting MASH from Ribo Life Science

on

Madrigal Pharmaceuticals entered an exclusive global licensing agreement with Suzhou Ribo Life Science and Ribocure Pharmaceuticals for six preclinical siRNA programs targeting MASH on February 11-12, 2026.246

The deal includes a $60 million upfront payment to Ribo, up to $4.4 billion in milestone payments, and royalties on net sales.123456

siRNAs utilize Ribo's GalSTAR platform for liver-targeted gene silencing to reduce disease-driving proteins in MASH.2346

Madrigal plans to combine these siRNAs with its FDA-approved MASH therapy Rezdiffra and start IND-enabling activities for initial candidates in 2026.12356

This expands Madrigal's MASH pipeline, now with over 10 programs, complementing Rezdiffra, MGL-2086, and ervogastat.235

Sources:

1. https://pharmaphorum.com/news/madrigal-builds-mash-44bn-ribo-alliance

2. https://www.pharmanow.live/latest-news/madrigal-sirna-mash-ribo-deal

3. https://www.biospace.com/deals/madrigal-dives-further-into-mash-with-up-to-4-4-b-sirna-deal-with-chinese-biotech

4. https://www.prnewswire.com/news-releases/ribo-and-ribocure-announce-exclusive-global-licensing-agreement-with-madrigal-for-novel-sirna-therapeutics-targeting-mash-302685018.html

5. https://www.fiercebiotech.com/biotech/madrigal-pens-44b-deal-ribos-sirna-programs-latest-rezdiffra-mash-play

6. https://www.globenewswire.com/news-release/2026/02/11/3236027/0/en/madrigal-expands-its-mash-pipeline-with-exclusive-global-licensing-agreement-for-six-preclinical-sirna-programs.html